Novo Nordisk announced it is lowering the cost of insulin by up to 70%. This follows a similar move by drug competitor Eli Lilly earlier this month and comes after years of pressure from activists, lawmakers and people with diabetes. It also puts pressure on Sanofi, the other major insulin manufacturer in the U.S., to follow suit. Last week, Congressmember Cori Bush and Senator Bernie Sanders introduced the Insulin for All Act to cap insulin prices at $20 per vial.